AC Immune SA (NASDAQ: ACIU) enters the second half of 2026 with three near-term clinical readouts, a fresh FDA Fast Track designation, and a CHF 75.4 million ($92 million) liquidity pool that management states funds the company into the fourth quarter of 2027. The most recent material event is the August 11, 2026 announcement that the FDA granted Fast Track and cleared the IND for ACI-7104, the company's wholly-owned anti-alpha-synuclein active immunotherapy in early Parkinson's disease, opening the door to U.S. clinical sites for the ongoing Phase 2 VacSYn study. Six days earlier, on August 5, 2026, the company filed the H1 2026 6-K disclosing a 67.9% reduction in net loss to CHF 12.9 million ($15.8 million) versus CHF 40.2 million ($49.0 million) a year earlier, with revenue of CHF 16.2 million ($19.8 million) up 7.1x on a CHF 10 million Lilly Morphomer amendment and a CHF 1 million milestone plus a $12 million Takeda milestone tied to the ABATE trial AD4 cohort.
The equity is, in our view, a clinical-stage platform priced for binary outcomes, not a cash-burn story. The market is assigning a roughly $250 million enterprise value to a pipeline that includes two active-immunotherapy programs in clinical development, a small-molecule NLRP3 inhibitor in Phase 1, a wholly-owned TDP-43 PET tracer with first-in-class data, and >$4.5 billion in potential milestone payments across collaborations with Takeda, Lilly, and Janssen. The thesis rests on whether H2 2026 VacSYn Part 1 week-100 data, ACI-19764 Phase 1 single-ascending-dose/multiple-ascending-dose results, and the Morphomer a-syn lead declaration collectively re-rate the wholly-owned pipeline enough to justify the partnered-program optionality that the deferred revenue balance of CHF 90.3 million ($110.5 million) implies.
The single load-bearing risk is execution: a clean VacSYn readout in H2 2026 de-risks ACI-7104 and unlocks the Takeda $2.1 billion option-fee optionality, while a weak or ambiguous readout forces a re-rating of the equity toward cash, not pipeline. The H1 2026 numbers show the company is operating on the right side of that equation, with operating cash burn compressed to CHF 15.6 million ($19.1 million) from CHF 34.4 million ($42.0 million) a year earlier, and management is guiding to liquidity into Q4 2027 even before any new milestone payments. The single falsifiable clock is the H2 2026 VacSYn Part 1 week-100 readout; the second is ACI-19764 Phase 1 SAD/MAD data; the third is the Morphomer a-syn lead declaration.